Ventrus Biosciences (VTUS) Trading Near Cash Value Says Cantor Fitzgerald
Tweet
Share
E-mailGet Alerts VTUS Hot Sheet
Price: $1.45 --0%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Analysts at Cantor Fitzgerald continue to see value in shares of Ventrus Biosciences (NASDAQ: VTUS), though the stock has declined 75 percent this year.
"VTUS has traded down to practically cash value. At the current stock price of $2.06 and 13M shares outstanding, the market cap is approximately $26.8M, whereas the company has a cash balance of $23.6M (and will not need financing until late 2013, in our view)," said analyst Irina Rivkind.
She thinks the market is assigning minimal value to the company's Phase III asset in anal fissure, which should be market-ready by end of 2014.
"Management plans to report the results of its anal fissure market research in a few weeks, which we believe should re-energize the stock to some extent," added Rivkind.
Cantor Fitzgerald maintained a Buy on Ventrus Biosciences (NASDAQ: VTUS) with a price target of $7.00. The stock was upgraded from Hold on August 10th.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $2.06 yesterday.
"VTUS has traded down to practically cash value. At the current stock price of $2.06 and 13M shares outstanding, the market cap is approximately $26.8M, whereas the company has a cash balance of $23.6M (and will not need financing until late 2013, in our view)," said analyst Irina Rivkind.
She thinks the market is assigning minimal value to the company's Phase III asset in anal fissure, which should be market-ready by end of 2014.
"Management plans to report the results of its anal fissure market research in a few weeks, which we believe should re-energize the stock to some extent," added Rivkind.
Cantor Fitzgerald maintained a Buy on Ventrus Biosciences (NASDAQ: VTUS) with a price target of $7.00. The stock was upgraded from Hold on August 10th.
For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.
Shares of Ventrus Biosciences closed at $2.06 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
- New Street Research Upgrades Micron Technology (MU) to Buy
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
